Syneron Bio raised a $150 million Series B round to advance peptide therapeutics, according to company reporting, building on its prior $100 million round from the previous year. The company plans to use the funding to support development of a drug class that seeks to combine some advantages of small molecules and biologics through peptide-based formats. The financing adds to a growing wave of investor interest in peptide platforms, particularly as peptide engineering and delivery continue to improve. For the pipeline landscape, additional cash can translate into faster IND-prep, expanded target programs, and more clinical entries—especially in indications where traditional biologics’ delivery or administration routes are limiting.